Wei Peng, MD
Pulmonary Disease · Salt Lake City, UTNPI 1295831865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Boehringer Ingelheim at 30.3% of the total. Reporting peaked in 2019 at $230 and has fallen 54.1% since, to $106 in 2025.
Across 22 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$144
- Phathom Pharmaceuticals, Inc.$106
- Merck$61
- Pfizer$35
- Gilead$29
- Viiv Healthcare Company$24
- plus $76 from 4 others
What the payments were for
- Food & beverage$44995%
- Education$255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $144 |
| Phathom Pharmaceuticals, Inc. | 1 | $106 |
| Merck | 5 | $61 |
| Pfizer | 2 | $35 |
| Gilead | 2 | $29 |
| Viiv Healthcare Company | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $20 |
| Harmony Biosciences LLC | 1 | $19 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$106
How this compares
$474 in reported general payments places this provider in the 55th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 24 | $1,401 |
| EnuloseLactulose | 22 | $1,116 |
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 21 | $591 |
| Omeprazole | 22 | $245 |
| Levothyroxine Sodium | 14 | $205 |
| Clonazepam | 15 | $122 |
| Oxycodone Hcl | 19 | $90 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.